The Cervical Screening Programme (cytology)
The Cervical Screening Programme aims to notify people of their results within 14 days.
The types of screening result you may get will depend on how your screening sample was tested. In some areas, the first test carried out on the cell sample is to look for abnormal cells (cytology).
In other areas, cell samples are tested first for human papilloma virus (HPV). This is called HPV primary screening. If this is the case, you will have received a leaflet about HPV primary screening with your screening invitation.
- Cervical samples are reported according to NHS Cervical Screening Program turnaround guidelines. The turnaround target is 14 days from sample taking to the patient in receipt of the result.
- Samples are only accepted on patients eligible for cervical screening and at the appropriate time intervals. Specimens are not accepted for clinical reasons, these patients should be referred to a Gynaecologist.
Diagnostic Cytology (non Gynae)
Diagnostic Cytology is the study of the microscopic anatomy of cells from people. It is commonly performed by examining cells under a light microscope, which have been stained and mounted on a microscope slide
Urgent requests are defined as those essential for the management of the patient. These should be highlighted by the requesting Clinician by writing ‘Urgent’ on the request form together with a contact telephone number.
Cases are reported by Specialty teams within Cellular Pathology. The turnaround time target is 10 days from sample taking to result issued.
All Frozen sections must be pre-booked by phoning 01622 227468
The laboratory requires 48 hours prior notice. This is to ensure availability of key lab staff, a reporting consultant and the readiness of the necessary equipment .
Histology is the study of the microscopic anatomy of cells and tissues of people. It is commonly performed by examining cells and tissues under a light microscope, which have been sectioned, stained and mounted on a microscope slide
Histopathology, the microscopic study of diseased tissue, is an important tool in anatomical pathology, since accurate diagnosis of cancer and other diseases usually requires histopathological examination of samples. Pathologists, are the personnel who perform histopathological examination and provide diagnostic information based on their observations.
A broadest definition of molecular pathology is the study of molecules in a disease state. In this context, the molecules studied are DNA, RNA and/or protein. Portions of DNA (known as genes) act as templates for the production of RNA which in turn acts as a template for the production of protein. Molecular pathology tests may look for the presence or absence of protein or RNA, or for an increase or decrease in the amount of these molecules.
Molecular Histopathology uses molecular testing to predict the response of certain ‘solid’ cancers to specific drugs. This predictive testing forms the basis of ‘personalised medicine’ for such cancer patients, and includes: HER2 testing in breast and gastric cancer; EGFR and ALK testing in lung cancer; BRAF testing in melanoma; and RAS testing in colorectal cancer. This form of predictive testing is currently a particular growth area in molecular pathology.